Partnering with Eremid Genomic Services, a specialty high-complexity genomics contract research organization and Certified Service Provider (CSP), BioSkryb Genomics a company specializing in single-cell and ultra-low-input multiomic solutions, has launched an Early Access Program for its new ResolveSEQ LongRead solution.

This program is designed to provide researchers with services that deliver a substantial leap in single-cell whole-genome long-read sequencing, offering significantly greater genomic coverage and sensitivity than previously published methods.

ResolveSEQ LongRead achieves an impressive 75-92% coverage across diverse sample types from a single cell by integrating a specially tuned version of BioSkryb’s proprietary Primary Template-directed Amplification (PTA) technology with Eremid’s custom PacBio library preparation. This innovative approach yields over 70% sensitivity for detecting both single-nucleotide variants (SNVs) and complex genomic regions simultaneously within the same cell, establishing a new benchmark for accuracy and completeness in the field.

According to BioSkryb CSO Dr. Charles Gawad, the solution directly addresses the challenge of genome coverage loss inherent in existing long-read sequencing technologies, enabling researchers to accurately assess complex structural rearrangements, measure lengths of gene expansions or tandem repeats, and phase SNVs in the same single cell for the first time. The technology is expected to drive meaningful discoveries across fields such as oncology, neurology, and cell and gene therapy by empowering researchers to resolve translocations and copy number variations (CNVs), detect on- and off-target genome edit locations, and reveal heterogeneity of structural alterations in conjunction with phased SNVs. Eremid CSO Julien Curaba affirmed that this partnership leverages BioSkryb’s PTA technology to meet the high demands for accuracy and uniformity from their clients, delivered through Eremid’s CLIA-certified, CAP-accredited laboratory.